Back to top
more

Virtus LifeSci Biotech Clinical Trials ETF: (BBC)

(Delayed Data from NYSE) As of Feb 13, 2026 03:30 PM ET

$39.91 USD

39.9101
13,946

-0.39 (-0.97%)

Volume: 13,946

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

After-Market: $39.86 -0.05 (-0.13 %) 7:58 PM ET

Zacks News

Sanghamitra Saha headshot

3 ETFs Braving Inflationary Fears in Past Three Months

These ETFs have braved the inflationary fears in the past three months and topped the S&P 500.

Zacks Equity Research

The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO

BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.

Sweta Killa headshot

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Sanghamitra Saha headshot

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Sweta Killa headshot

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Sweta Killa headshot

4 Sector ETFs That Survived Market Turmoil in June

June has proved to be a brutal month for the stock market. The combination of factors such as decades-high inflation, the Russia-Ukraine conflict and Fed¿¿¿s aggressive tightening policy are weighing heavily on investors' sentiment.

Sanghamitra Saha headshot

ETFs Winners of S&P 500's Second Best Week in 2022

The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.

Sweta Killa headshot

Top and Flop ETFs of Q1

We have highlighted the three ETFs each from the best and worst performing zones of first-quarter 2022.

Sweta Killa headshot

Top and Flop ETFs At Midway Q1

We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.

Sweta Killa headshot

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.